KPV: What It Is, What the Research Shows, and How to Verify Purity

KPV is a synthetic tripeptide of lysine, proline and valine (Lys-Pro-Val) that matches residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the human body makes. Published research on it consists of cell-culture and rodent studies; there are no completed controlled human trials, and it is not approved as a drug in any country.

What is KPV?

KPV is a synthetic tripeptide – a chain of exactly three amino acids: lysine, proline and valine. Chemists write it with the one-letter codes for those residues, K-P-V, which is where the name comes from.

Those three residues are the tail end of a larger natural hormone called alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid signalling molecule involved in pigmentation and in immune signalling. KPV corresponds to residues 11 to 13 of that hormone – its C-terminal fragment. Researchers isolated this piece because experiments suggested the short tail retained measurable activity in cell assays without the rest of the molecule.

Because it is so short, KPV behaves differently from larger peptides in one important way: peptides of two or three residues can be carried into cells by dedicated transporter proteins, rather than having to be broken down first. That detail turns out to be central to the research below.

This page does not print a CAS number. Suppliers quote different registry numbers for KPV depending on the salt form supplied (an acetate or trifluoroacetate salt is a different registered substance from the free peptide, and has a different mass). The number that matters is the one on the certificate for the batch in hand, cross-checked against the mass-spectrometry result on the same document.

What the research has actually examined

KPV research is concentrated in gastrointestinal and cell-signalling models. Read the “Model” line first: every study below is a cell-culture experiment or a rodent experiment.

The pattern is consistent and worth stating plainly: KPV has a small, coherent preclinical literature centred on intestinal and epithelial cell models, spread across a handful of research groups, and no controlled human trials at all. The mechanism work is comparatively well-specified for a research peptide. The human evidence base is empty.

How researchers think it works

Two threads run through the literature.

The first is transport. PepT1 is a protein in the intestinal lining whose job is to carry di- and tripeptides out of the gut and into cells. Because KPV is a tripeptide, it fits that transporter. Dalmasso and colleagues reported uptake by this route at very low concentrations, which is the mechanistic reason a three-residue peptide gets studied in gut models at all.

The second is melanocortin receptor signalling. Because KPV is a fragment of alpha-MSH, researchers have asked whether it acts through the same receptor family the parent hormone uses. The human airway cell work points at MC3 receptor involvement. Other papers report activity that appears to be receptor-independent, so this is not settled.

Both threads describe mechanisms observed in cells and animals. They explain why researchers study the molecule. They do not establish what it does in a human being.

What is known about safety

• No human safety data. There are no completed, published, controlled human trials of KPV. No human safety profile exists. The safety question is examined in full in is KPV safe? what the research actually shows.
• Preclinical work reported activity at low concentrations, which is often described as a favourable sign in early research, but low active concentrations in a cell assay say nothing about safety in a person.
• Not approved anywhere. KPV is not an approved drug in any country. Its parent hormone’s receptor family is targeted by some approved medicines, but that does not extend any approval or safety finding to this fragment.
• Fragment status cuts both ways. Being a piece of a natural human hormone is sometimes presented as evidence of safety. It is not. Fragments can behave differently from their parent molecule, which is precisely why they are studied separately.

PeptSelect does not publish preparation or usage guidance for KPV, or for any peptide. Not as a legal formality – for an unapproved compound with no human safety data, there is no such guidance that could responsibly be given.

How to verify what you actually received

Short peptides are, in one specific way, harder to verify than long ones: there is less molecule to identify, and small synthesis errors move the mass by very little. That makes the certificate more important, not less.

On a KPV batch certificate, the things worth checking are:

• Identity by mass – a mass-spectrometry result consistent with the tripeptide and the stated salt form, not just a name typed on a page.
• Purity from a real chromatogram – an HPLC trace you can actually look at. Our guide to reading a chromatogram covers what a clean one looks like.
• Net peptide content – for a very small peptide, the gap between powder weight and actual peptide mass matters proportionally more. See net peptide content.
• Batch matching – the lot number on the certificate matching the batch number on your order confirmation. Our batch verification guide covers the workflow.
• A named independent lab, not an anonymous “tested” stamp – see why third-party testing matters.

Every PeptSelect batch is matched to a published third-party certificate in the COA Vault, and the full testing process is documented in How we test.